Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 May:172:72-77.
doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

Lucia Musacchio  1 , Margherita Turinetto  2 , Laura Arenare  3 , Michele Bartoletti  4 , Daniela Califano  5 , Valentina Tuninetti  2 , Claudia Marchetti  1 , Gennaro Cormio  6 , Vera Loizzi  6 , Carmela Pisano  7 , Vanda Salutari  1 , Giorgio Valabrega  2 , Domenico Priolo  8 , Sabrina Chiara Cecere  7 , Jole Ventriglia  7 , Francesco Raspagliesi  9 , Francesco Perrone  3 , Anna Fagotti  10 , Domenica Lorusso  10 , Giovanni Scambia  10 , Sandro Pignata  11
Affiliations
Multicenter Study

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

Lucia Musacchio et al. Gynecol Oncol. 2023 May.

Abstract

Objective: The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.

Methods: In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group.

Results: Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 - NR) and 22.63 months (95% CI 15-39.24) (p-value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum-based CT alone. Median PFS were 37.1 months (95% CI: 13.42-40.56) and 11.22 months (95% CI: 8.26-15.63) (p-value 0.013), respectively.

Conclusions: Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest CM reports consultant/advisory board for Clovis, Pharmamar, GSK, Astrazeneca, Arquer diagnostic and travel accommodation from Pharmamar and Roche. VS reports honoraria from GSK, PharmaMar, Roche, MSD, EISAI, Clovis, Oncology, AstraZeneca. FR reports honoraria from GSK, Pharmamar, Clovis, MSD and Roche. FP reports honoraria for educational and advisory activity from Incyte, GSK, Eli Lilly, Ipsen, Astellas, AstraZeneca, Roche, BMS, Bayer, Clovis, Pierre Fabre and grants for clinical trials to his institution from Roche, Astra Zeneca, Pfizer, MSD, Bayer, Incyte Taiho, Janssen, Exelixis, Ailenor, Daiichi Sankyo. AF reports relationship with commercial interests with AstraZeneca, MSD, Johnson & Johnson and Pharmamar. DL reports research funding from Clovis, GSK and MSD, personal interests with AstraZeneca, Clovis Oncology, GSK, Pharmamar, MSD and financial interests with Clovis, Genmab, GSK, MSD. Board of Directors, GCIG (Gynecologic Cancer Inter Group). GS reports research support from MSD and honoraria from Clovis Oncology. Consultant for Tesaro and Johnson & Johnson. SP reports honoraria from AstraZeneca, MSD, Roche, Pfizer, Clovis, GSK, Pharmamar and research funding from MSD, Roche, Astrazeneca and Pfizer. LM, MT, LA, MB, DC, VT, GC, VL, CP, GV, SCC, JV have nothing to disclose.

Publication types

LinkOut - more resources